Eribulin and irinotecan for refractory or recurrent Ewing sarcoma: A retrospective study.

• DOI: 10.1200/jco.2024.42.16_suppl.e23502
• Publication Date: 2024-06-03T21:07:03Z
• Authors: Jie Xu; Lu Xie; Xin Sun; Kuisheng Liu; Xin Liang; Xiaodong Tang
• Keywords: Eribulin; Ewing's sarcoma; Refractory (planetary science); Trabectedin

e23502 Background: The effectiveness of eribulin and irinotecan in treatment xenograft models Ewing sarcoma is well-established but little clinical data has been reported. Encouraging results from preclinical a shortage temozolomide our hospital have prompted the administration as substitute for vincristine combination at institution 2022 to 2023 an off-label way. Methods: We retrospectively reviewed medical records patients treated refractory or recurrent with 1.4mg/m 2 D 1,8 20mg/m /d 1-5,8-12 21 day intervals (ERII) Peking University People’s Hospital. Results: Finally, total 17 median age 18.6 years were 77 courses ERII between February 2023. objective response rate was 35.3%, disease control 58.9% event-free survival (EFS) 2.07 months. 35.3% had 6 months EFS overall 66.9%. Grade 3 4 toxicities observed 37.6% 64.7% patients, myelosuppression, especially neutropenia, being most common diarrhea / abdominal pain second common. In dx5x2 VIT protocol later portion given two days after end early portion. However, this regimen eribulin, time interval start 5 days. dose intensity reduced by 21% per cycle. delayed mostly because unrecovered myelosuppression. Conclusions: efficacy safety second-line inferior historical reports same institute. There no need further prospective trials on unless mechanisms synergy biomarkers are identified. [Table: see text]